Evogene Reports Nasdaq Grants Additional 180-Day Period to Regain Minimum Bid Price Compliance
Evogene (NASDAQ: EVGN) received a 180-day extension from Nasdaq to comply with the minimum $1.00 bid price requirement, ending March 29, 2027. The company must maintain a closing bid price of at least $1.00 for 10 consecutive days to regain compliance. Evogene plans to explore options like a reverse share split if needed. Trading continues on Nasdaq under 'EVGN'.
How this was made
The 30-second read
Why it matters
The compliance extension signals continued listing risk, which may keep the stock under pressure until the bid price recovers or a corporate action (e.g., reverse split) is taken.
Market read
The news is relevant for traders holding or considering EVGN, as the compliance risk may affect price direction in the near term.
What to watch
Potential upcoming financing, partnership announcements, or product milestones could offset the compliance risk.
Background
Evogene is a computational chemistry firm listed on Nasdaq (EVGN) and TASE, currently trading below the $1 minimum bid price requirement.
Ticker impact
Nasdaq granted Evogene an additional 180‑day period to regain $1 minimum bid price compliance, extending the deadline to March 29, 2027.
likely pressure as the market prices in the risk of delisting if the bid stays below $1
The company remains below the $1 threshold and faces a potential delisting, which typically depresses share price until compliance is achieved.
Market effects
Minimal impact on the broader biotech/ag‑chem sector; the issue is company‑specific.
Limited to US and Israeli markets where the stock trades.
Low; no broader market ripple.
Counterpoint
If the company successfully executes a reverse split or raises capital, the compliance risk could be mitigated, offering a short‑term buying opportunity.
Key entities
- CompanyEvogene Ltd.
Computational chemistry firm facing Nasdaq bid‑price compliance issue.
- RegulatorNasdaq Stock Market LLC
Provided the additional compliance period.
.jpg&w=2048&q=75)
